Impact on the carotid intima-medial thickness and safety of rosuvastatin in Chinese patients with carotid atherosclerosis: a meta-analysis.
- Author:
Xueru FENG
1
;
Jingwei ZHANG
;
Meilin LIU
2
;
Xueying LI
Author Information
- Publication Type:Journal Article
- MeSH: Carotid Artery Diseases; diagnostic imaging; drug therapy; Carotid Intima-Media Thickness; Female; Fluorobenzenes; therapeutic use; Humans; Male; Pyrimidines; therapeutic use; Rosuvastatin Calcium; Sulfonamides; therapeutic use
- From: Chinese Journal of Cardiology 2014;42(3):247-253
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of rosuvastatin in Chinese patients with carotid atherosclerosis.
METHODA systematic search of Pubmed, EMBase, CENTRAL, CBMdisc, CNKI and WANFANG databases up to January 2013 was performed to identify studies comparing rosuvastatin with a placebo or other statins on carotid intima-medial thickness (IMT) with a minimum follow-up of 6 months in Chinese patients. Meta-analysis was performed by using RevMan 5.0 software after the strict evaluation of the methodological quality of the included studies independently by two reviewers.
RESULTSTwenty-eight studies involving 1 392 individuals were included in this review. The pooled weighted mean difference (WMD) between rosuvastatin and placebo or control on IMT was 0.28 mm (95%CI 0.14-0.42, P < 0.01), with 0.31 mm (95%CI 0.14-0.49, P < 0.01) on 6-8 months and 0.16 mm (95%CI 0.05-0.27, P = 0.005) on 12 months, respectively. Analysis on studies in core journals showed the WMD between rosuvastatin and placebo or control on IMT was 0.18 mm (95%CI 0.09-0.27, P < 0.01). The WMD between rosuvastatin and other statins on IMT was 0.06 mm (95%CI 0.04-0.08, P < 0.01). The WMD between rosuvastatin and placebo or control on plaque score was 0.89 (95%CI 0.78-0.99, P < 0.01). The WMD between rosuvastatin and placebo or control on plaque area was 1.46 (95%CI 0.67-2.25, P < 0.01).Reports of adverse effect were elevated liver enzyme (2.30%, 19/825), elevated muscle enzyme (0.73%, 6/825), muscle aches (0.61%, 5/825).
CONCLUSIONSRosuvastatin therapy is effective and safe to decrease IMT in Chinese patients with carotid atherosclerosis.